SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)
CREATIVE BIOMOLECULES, INC.
----------------------------
(Name of Issuer)
Common Stock, $.01 par value
----------------------------
(Title of Class of Securities)
225270 10 7
----------------------------
(CUSIP Number)
Donna J. Roberts, Esq.
Secretary
The Dow Chemical Company
2030 Dow Center
Midland, Michigan 48674
(517) 636-1000
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Check the following box if a fee is being paid with this statement [ ].
Page 1 of 4
<PAGE> 2
CUSIP No. 225270 10 7
- --------------------------------------------------------------------------
1) Name of Reporting Person and its The Dow Chemical Company
I.R.S. Identification Number 38-1285128
- --------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ X ]
- --------------------------------------------------------------------------
3) SEC Use Only
- --------------------------------------------------------------------------
4) Citizenship or Place of Delaware
Organization
- --------------------------------------------------------------------------
Number of 5) Sole Voting Power 0
Shares -----------------------------------------------------------
Beneficially 6) Shared Voting Power 0
Owned by -----------------------------------------------------------
Each 7) Sole Dispositive Power 0
Reporting -----------------------------------------------------------
Person With 8) Shared Dispositive Power 0
- --------------------------------------------------------------------------
9) Aggregate Amount Beneficially 0
Owned by Each Reporting Person
- --------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
- --------------------------------------------------------------------------
11) Percent of Class Represented 0.0%
by Amount in Row (9)
- --------------------------------------------------------------------------
12) Type of Reporting Person CO
- --------------------------------------------------------------------------
<PAGE> 3
This Amendment No. 2 amends the Statement on Schedule 13G of The Dow
Chemical Company ("Dow") dated December 7, 1992, as amended through the
date hereof, with respect to the Common Stock of Creative Biomolecules,
Inc. (the "Issuer"). This Amendment is filed solely to reflect the fact
that as of June 28, 1995, Dow is no longer the beneficial owner of any
securities of the Issuer.
Items 2, 4 and 5 of Dow's Statement on Schedule 13G with respect to
securities of the Issuer are hereby amended to read as follows:
ITEM 2.
- -------
(a) Name of Person Filing: This Schedule is filed on behalf of The
Dow Chemical Company ("Dow") with respect to its potential deemed indirect
beneficial ownership of Common Stock of the Issuer through Dow's beneficial
ownership of a majority of the outstanding common stock of Marion Merrell
Dow Inc. ("MMD"). MMD is the direct beneficial owner of the securities
previously reported in Schedule 13G filings as beneficially owned by Dow,
as to which Dow disclaims beneficial ownership.
(b) Address of principal business office: 2030 Dow Center, Midland,
Michigan 48674.
(c) Citizenship: Delaware.
(d) Title of Class of Securities: Common Stock, par value $.01 per
share.
(e) CUSIP Number: 225270 10 7
ITEM 4. OWNERSHIP.
- ------- ----------
On June 28, 1995, Dow disposed of its ownership interest in MMD and
thus no longer has a beneficial interest in any of the Issuer's Common
Stock.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
- ------- ---------------------------------------------
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following [X].
<PAGE> 4
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
THE DOW CHEMICAL COMPANY
Date: July 10, 1995 By: /s/ Enrique C. Falla
--------------------------- ------------------------------------
Enrique C. Falla
Executive Vice President and
Chief Financial Officer
